Call for Applications: The Sigourney Trust Annual Award Recognizes Top Psychoanalysts


In light of many crises taking place today, it is important to celebrate and recognize the contribution of psychoanalytic practice to society.

Established in 1989, The Sigourney Award offers independent, international recognition and a substantial prize for outstanding work that advances psychoanalysis and psychoanalytic thought. The deadline to apply for this year’s award is October 4, 2020 (scroll down for video details).

The Sigourney Trust was founded by Mary Sigourney, a licensed psychotherapist, publisher, and community activist. A fiercely independent thinker, she believed that rewarding and publicly acknowledging individual achievements would inspire and influence the next generation of psychoanalytic thought. She established The Sigourney Trust to encourage new and outstanding contributions to psychoanalysis and psychoanalytic thought. She had a passionate interest in psychoanalysis and understood its ability to benefit and extend human conversation across various disciplines.

To date, 129 award recipients from 21 countries represent Ms. Sigourney’s global vision. The Sigourney Award recipients’ have submitted ground-breaking work which has significantly contributed to human affairs on topics ranging from neuroscience to feminism. Interested professionals can apply for the award at

Given the multitude of crises today that we are experiencing across the globe, Myerson noted it is important to celebrate those doing their best work to benefit society and recognize the importance of psychoanalytic practice in its many forms.

Dr Myerson is a licensed psychoanalyst and clinical psychologist, and a training and supervising psychoanalyst at the Center for Psychoanalytic Studies in Houston, Texas. He is currently an adjunct professor in the Department of Psychiatry where he provides consultation and instruction to mental health professionals.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.